
A new report from RSA Group has revealed that European biotech companies are “significantly outperforming” their US counterparts in terms …

The European Commission has granted Tesaro’s Zejula (niraparib) marketing approval in Europe, it has emerged. Zejula is a poly (ADP-ribose) …

Novartis’s Tasigna (nilotinib) has received European Commission approval for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in …

Boehringer Ingelheim has announced that Cyltezo, its biosimilar of Abbvie’s Humira, has received marketing authorisation approval from the European Commission, …

Novartis has announced that its targeted therapy Rydapt (midostaurin) has received EU approval in the two rare cancer indications: newly …

As a consequence of the triggering of Article 50 and the UK’s exit from the EU, the EMA – currently …

Bristol-Myers Squibb has announced that its flagship immunotherapy treatment Opdivo (nivolumab) has secured its eighth approval in Europe as the …

Janssen has announced that its CD38-directed monoclonal antibody Darzalex (daratumumab) has expanded its indication with a thumbs-up from the European …

Drug pricing is a topic that has become headline-friendly over the past year. It has come to dominate media coverage …

The UK biotechnology sector is going from strength to strength, having raised an “unprecedented” £900 million on the London Stock …

Leading UK oncologists have written an article in the May issue of The Lancet, strongly urging Britain to remain in …

Boehringer Ingelheim is beginning a new push in lung disease across Europe after being approved by regulators in nine countries …
Sanofi and Merck are looking forward to a successor to their blockbuster Gardasil now that the European Commission has granted …

Takeda will be teaming up with Japan’s National Cancer Center (NCC) to develop new cancer drugs. The two organisations have …

AbbVie’s combination hepatitis C treatment looks set to be approved in yet another country after being granted priority review in …